HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro chemosensitivity of human lung cancer for vindesine.

Abstract
Firstly, the effect of Vindesine was studied on four different human lung carcinoma cell lines (two small cell, one adeno and one squamous cell) with the Fast Green dye exclusion assay (FGA) and the clonogenic assay. Both methods demonstrate a clear dose response relationship and the estimated drug efficacy is similar for both assays. In the cell lines with the longest doubling time a plateau was reached in the FGA, most probably due to the short culture time in this assay. Secondly, the effect of Vindesine on human lung carcinoma specimens (n = 64), mainly bronchoscopy biopsies (n = 48), was evaluated with the FGA. The FGA has merits as predictive test in the clinic in the situation that only a small number of cells can be obtained. In this study, due to the high number of bronchoscopy biopsies only in a minority of cases a conclusion could be obtained (37.5%).
AuthorsE G De Vries, C Meijer, N H Mulder, P E Postmus
JournalEuropean journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 23 Issue 1 Pg. 55-60 (Jan 1987) ISSN: 0277-5379 [Print] England
PMID3036536 (Publication Type: Journal Article)
Chemical References
  • Vindesine
Topics
  • Adenocarcinoma (drug therapy)
  • Carcinoma, Small Cell (drug therapy)
  • Carcinoma, Squamous Cell (drug therapy)
  • Cell Line
  • Cell Survival (drug effects)
  • Dose-Response Relationship, Drug
  • Humans
  • Lung Neoplasms (drug therapy)
  • Tumor Stem Cell Assay
  • Vindesine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: